Lead Extraction in CIED Endocarditis: Australian Outcomes

Cardiac implantable electronic device endocarditis represents a severe and increasingly common complication among patients living with pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronisation therapy devices. The infection can involve the generator pocket, the intravascular leads, and the endocardial surface, often presenting with bacteraemia, sepsis, or vegetation formation. As implantation volumes rise across the Asia-Pacific region, the clinical burden of device-related infection has grown in parallel, creating significant challenges for electrophysiologists, infectious disease specialists, and cardiac surgeons.

Complete removal of all hardware, including the generator and every transvenous lead, has become the cornerstone of curative therapy for established CIED endocarditis. Antibiotic therapy alone is associated with high relapse and mortality rates, particularly when vegetations are large or caused by Staphylococcus aureus. Transvenous lead extraction, performed in specialised centres, offers a definitive path to eradication and subsequent reimplantation once the patient is clinically stable.

In Australia, where an ageing population is increasingly receiving these devices, outcomes following extraction reflect national strengths such as universal healthcare through Medicare, the regulatory oversight of the Therapeutic Goods Administration, and a network of high-volume tertiary centres in cities including Sydney, Melbourne, Brisbane, and Perth. Local realities, from regional referral logistics to Indigenous health disparities, shape how these procedures are delivered and evaluated.

Understanding CIED Endocarditis and Why Lead Extraction Matters

Device infection spans a spectrum from superficial pocket erythema to deep endocarditis with septic emboli. Modified Duke criteria adapted for electrophysiology devices guide diagnosis, integrating clinical findings, blood cultures, and imaging, with transoesophageal echocardiography central to identifying lead-adherent vegetations. When endocarditis is confirmed, complete hardware removal is supported by decades of evidence demonstrating that retained devices sustain infection, encourage biofilm formation, and resist antimicrobial penetration.

Extraction decisions carry weight because leads dwelling for years become adherent to venous structures, myocardium, and valves through fibrosis and calcification. Procedure-related risks include cardiac tamponade, tricuspid valve injury, and pulmonary embolism, yet contemporary outcome data show that the mortality benefit of complete removal far outweighs procedural hazard. Most patients who undergo successful extraction and complete antimicrobial therapy enjoy a favourable outlook, often returning to device therapy after a defined infection-free interval.

Patient Selection and Pre-Procedural Assessment

Careful selection underpins safe extraction. Pre-procedural evaluation includes lead dwell time, comorbidities, renal function, anticoagulation status, and imaging to gauge adherence. Patients with dwell times exceeding ten years, multiple abandoned leads, or severe comorbidity typically benefit from referral to high-volume operators. Australian centres apply risk stratification tools such as the ELECTRIcal Registry-derived scores to estimate major complication risk.

Imaging with computed tomography of the chest offers additional insight into lead course and proximity to critical structures. Telehealth-based pre-procedural discussion between regional cardiologists and metropolitan extraction specialists has become essential, particularly for patients in Western Australia and far north Queensland. A multidisciplinary team, comprising cardiac electrophysiologists, cardiac surgeons, infectious disease physicians, and anaesthetists, ensures surgical backup is immediately available and antimicrobial therapy is optimised.

Decisions about reimplantation timing are made jointly with the patient and family, balancing the risk of recurrent infection against the consequences of prolonged absence of pacing support. Some patients with low pacing dependency may be managed with temporary transvenous systems or no device at all during the infection window, while those with high dependency may require urgent reimplantation with extended antimicrobial cover.

Techniques and Tools Used in Transvenous Lead Extraction

Modern transvenous extraction follows a stepwise escalation from simple traction to laser sheaths, rotating mechanical sheaths, and ultimately open surgical removal. Locking stylists reinforce lead bodies, while powered sheaths dissect fibrotic and calcified tissue. Tool choice depends on operator preference, lead characteristics, and institutional availability. Vacuum-assisted systems, now offered in several Australian tertiary hospitals, have expanded percutaneous options for high-risk cases.

For vegetations exceeding 20 mm, some operators favour surgical extraction as first-line therapy, though experienced teams can manage many cases percutaneously. Procedural success is generally defined as complete removal without major complication, with partial removal acceptable only when clinically justified. Australian centres perform most extractions under general anaesthesia with invasive monitoring, transoesophageal guidance, and immediate surgical backup, typically in operating theatres rather than catheterisation laboratories.

Post-procedural care includes observation for pericardial effusion, haemodynamic instability, and signs of recurrent infection. Patients are typically monitored in a coronary care or high-dependency unit for at least 24 hours, with serial haemoglobin and echocardiographic checks as clinically indicated.

Clinical Outcomes: Success Rates and Procedural Complications

Outcomes of lead extraction in CIED endocarditis have been extensively studied. Procedural success rates for complete removal exceed 90% in experienced centres, and major adverse event rates range from 1% to 4%. Procedure-attributable mortality remains below 1%, though in-hospital mortality across the broader infected cohort can reach 5% to 15%, reflecting the severity of underlying illness. Australian data align with international figures, with most centres reporting procedural success above 95%.

Complications include cardiac tamponade, haemothorax, pulmonary embolism, and pneumothorax. Predictors of adverse events include advanced age, severe sepsis, large vegetations, renal impairment, and limited operator experience. For further procedural context, ventricular tachycardia ablation challenges explores related complexities in cardiac electrophysiology.

Long-term follow-up centres on durability of infection eradication and timing of reimplantation. Current practice favours waiting at least 14 days after negative blood cultures, although intervals may extend for complex infections. Patients who no longer require pacing may transition to leadless pacemakers or subcutaneous ICDs, reducing future infection risk.

Mortality Predictors and Long-Term Prognosis

Survival after CIED endocarditis depends heavily on host and pathogen factors. Staphylococcus aureus infection, prosthetic valve involvement, dialysis-dependent renal failure, and immunosuppression all portend higher mortality. Frailty, increasingly prevalent among older Australians, also shapes post-discharge survival and quality of life.

Reinfection is a recognised concern, particularly in patients with chronic indwelling catheters, advanced heart failure, or diabetes. Meticulous pocket care, surveillance, and patient education remain essential, with prolonged suppressive antibiotics considered in select cases. Long-term arrhythmia management requires reassessment of the original device indication; many patients retain a pacing or defibrillation indication, while others transition to alternative therapies integrated with their general practitioner and local cardiologist.

Psychosocial recovery also deserves attention. Hospitalisation for device infection can be prolonged, and patients may experience anxiety about future procedures or fear of recurrent infection. Cardiac rehabilitation programs tailored to patients with device infections are beginning to emerge in major Australian centres, offering structured exercise, education, and peer support.

Australian Healthcare System Considerations and Patient Access

Specialised lead extraction is concentrated in metropolitan tertiary hospitals, posing logistical challenges for residents of regional and remote communities. Medicare and the Pharmaceutical Benefits Scheme fund device implantation and follow-up, but complex extraction and surgical backup require institutional investment that is uneven across jurisdictions. Patients from Hobart, Darwin, or regional New South Wales often travel substantial distances, with air retrieval services relevant in time-sensitive cases.

Indigenous Australians carry a disproportionate burden of cardiovascular disease and comorbidities, complicating the presentation and management of CIED endocarditis. Cultural safety, community engagement, and partnership with Aboriginal Community Controlled Health Organisations are increasingly recognised as essential. National device registries, coordinated through the Cardiac Society of Australia and New Zealand, inform quality assurance and resource allocation, while continued research into antimicrobial prophylaxis and biofilm prevention remains vital.

Workforce training presents an additional consideration. Lead extraction is a high-skill, low-volume procedure, and ensuring adequate operator experience requires deliberate training pipelines, proctoring arrangements, and credentialing standards. Several Australian centres now offer formal fellowship positions in complex device management, helping to build the next generation of extraction specialists.

Future Directions and Research Priorities

The field continues to evolve, with next-generation laser and rotating sheath designs promising more efficient tissue ablation and reduced vascular injury. Bioabsorbable lead coatings and antimicrobial device envelopes are under investigation as preventive strategies. Australian investigators have prioritised risk-adjusted outcome benchmarks, optimised antimicrobial regimens, and integration of patient-reported outcomes. Complementary perspectives on arrhythmia management are available through the journal's educational resources.

Prevention efforts are gaining momentum. Pre-implant screening for Staphylococcus aureus carriage, chlorhexidine skin preparation, and targeted antibiotic prophylaxis have all reduced infection rates. The Therapeutic Goods Administration continues to evaluate device safety signals, and ongoing post-market surveillance will help identify emerging risks. By combining technological innovation, robust registries, and patient-centred care, the Australian cardiology community is positioned to improve outcomes for patients facing cardiac implantable electronic device endocarditis. To learn more about submitting work or engaging with the journal, readers are invited to visit the journal's about page.

Clinicians, researchers, and trainees are encouraged to contribute original research, case series, and review articles that advance the evidence base. Submissions shape clinical practice, inform guidelines, and support the Asia-Pacific community in refining care for patients with this challenging condition.